Recurrent B-Cell Non-Hodgkin Lymphoma · Fase 2 · NCT06723457
Biospecimen Collection, Computed Tomography, Epcoritamab, Lenalidomide
Reem Karmali · Abrir el resumen
Leukemia, Myeloid, Acute · Fase 2 · NCT07216443
Orca-T
Orca Biosystems, Inc. · Abrir el resumen
Mieloma múltiple · Fase 2 · NCT06083922
Cyclophosphamide, Bortezomib, Dexamethasone, Daratumumab
Memorial Sloan Kettering Cancer Center · Abrir el resumen
Acute Myelogenous Leukemia · Fase 2 · NCT05805605
Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide
Masonic Cancer Center, University of Minnesota · Abrir el resumen
Acute Myeloid Leukemia, Adult · Fase 2 · NCT04050280
Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO)
University of Maryland, Baltimore · Abrir el resumen
Sezary Syndrome · Fase 2 · NCT04256018
Mogamulizumab, LD TSEBT
Stanford University · Abrir el resumen
Linfoma de células B grandes · Fase 2 · NCT07316010
Leukapheresis, Lymphodepleting Chemotherapy
M.D. Anderson Cancer Center · Abrir el resumen
Recurrent Follicular Lymphoma · Fase 2 · NCT04587687
Bendamustine Hydrochloride, Brentuximab Vedotin
University of California, Davis · Abrir el resumen
Mieloma múltiple · Fase 2 · NCT06107738
Iberdomide, Daratumumab/rHuPH20 Co-formulation
Barbara Ann Karmanos Cancer Institute · Abrir el resumen
Acute Myeloid Leukemia, Relapsed, Adult · Fase 2 · NCT06802315
Intensity modulated total marrow irradiation, Cyclophosphamide (CTX), Fludarabine (Fludara), Busulfan (conditioning for ALLO Transplant)
University of Illinois Chicago · Abrir el resumen
Leucemia mieloide aguda · Fase 2 · NCT05401097
Azacitidine, Biopsy, Enasidenib, Ivosidenib
Alice Mims · Abrir el resumen
Aplastic Anemia · Fase 2 · NCT01624805
Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, Methylprednisolone
M.D. Anderson Cancer Center · Abrir el resumen
Chronic Lymphocytic Leukemia · Fase 2 · NCT07271667
Emavusertib, Zanubrutinib
Curis, Inc. · Abrir el resumen
Leucemia de células pilosas · Fase 2 · NCT00412594 · Artículos
Cladribine, Laboratory Biomarker Analysis, Rituximab
M.D. Anderson Cancer Center · Abrir el resumen